The successful manufacturing of intravenous JJP-1212 drug product ensures sufficient supply for initiation of JJP Biologics’s first-ever Phase I clinical trial in healthy subjects June…

JJP-1212, a first-in-class CD89 antagonist is being developed for the treatment of the rare autoimmune skin blistering disease linear IgA bullous dermatosis in addition to…